LeadArtis will join and contribute to the IACT project of the 7th European Framework programme.

01-11-2013

European Framework programmes (FPs) are the European Union’s main instrument for funding European Medical Research. They support the creation of multidisciplinary networks designed to promote the collaboration of health-related industries and integrate European-wide research, “as well as build a ‘critical mass’ of expertise and excellence”.

LeadArtis reports the generation of monospecific and bispecific hexavalent trimerbody® molecules

05-11-2012

LeadArtis S.L. announced the generation of multivalent and multispecific trimerbodies. By fusing single-chain variable fragments(scFv) with the same or different specificity to both N- and C-terminus of the trimerizing scaffold domain, monospecific or bispecific hexavalent molecules were successfully produced and secreted as soluble proteins by transfected mammalian cells.

Leadartis receives an Investment Award from BIOSPAIN 2012 Investment Forum

28-09-2012

This past 19-21 September, the Bilbao Exhibition Center hosted the BIOSPAIN 2012 Investment Forum. The Investment Forum offers a unique setting with pan-European networking for top entrepreneurs, R&D leaders, investors and experts from the Biotech sector. Companies seeking international financing or partners have the opportunity to present their business projects to a panel of interested investors and corporate partners.

LeadArtis collaborate on next-generation Trimerbody® products

22-03-2012

LeadArtis S.L. announced that published proof-of-concept data with a new Trimerbody® molecule. Trimerbody® molecules based in human collagen XV exhibited excellent antigen binding capacity, and demonstrated greater thermal and serum stability and resistance to protease digestion than conventional type XVIII Trimerbody® molecules.

LeadArtis is an Associated Company to the Immunotherapy Network

21-11-2011

The Immunotherapy Network IMMUNONET is a project approved under the Programme of Territorial Cooperation of the European Southwest Area (SUDOE-Interreg IV B). Bringing together leading international scientists, a stable team of cutting-edge research in Immunotherapy has been established in the southwestern Europe.

Leadartis present at the 5th edition of the Healthcare Investment, Forum Conference on November 3, 2011

04-11-2011

This past 3 November, the Medical Association of Barcelona (COMB) hosted the fifth edition of the Healthcare Investment Forum, a conference which aims to make private funding more accessible to companies in the healthcare sector that are in the growth phase and require an injection of up to 3 million euros of capital. Leadartis was one of the 11 companies selected, from more than 30 candidates, to present the project to more than 100 venture investors.

The CDTI has awarded Leadartis with a NEOTEC loan

01-09-2010

The Center for Industrial Technological Development (www.cdti.es), a Spanish governmental body dependent on the Ministry of Science and Innovation has granted a NEOTEC loan to Leadartis for the development of diagnostic and therapeutic candidates.

Leadartis is part of the Genoma España´s Technology Portfolio

01-02-2008

In 2008 LeadArtis signed an agreement with Genoma España, and it has been incorporated to its Technology Portfolio (www.gen-es.com.es). The agreement supported the creation of the company and represented an infusion of resources to finance LeadArtis´start-up activities.

Syndicate content

Latest News

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting
09-12-2016

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao
25-08-2016

Leadartis will participate in BioSpain 2016 to be held...